Back to search results

Medtronic 780G Insulin Pump for Type 1 Diabetes and Gastroparesis

This study is looking at how well and how safely the Medtronic 780G automated insulin delivery system works for adults who have both type 1 diabetes and gastroparesis (a condition where your stomach empties food too slowly). You might be able to join if you are at least 18 years old, have had type 1 diabetes for at least a year with a stable insulin plan, and have an HbA1c (a measure of average blood sugar) of 8.0% or higher. You also need to have a diagnosis of gastroparesis and be willing to use the Medtronic 780G system. The study will measure how much time participants spend with their blood sugar in a healthy range (70-180 mg/dL) over three months. The current recruitment status is unclear, and the study plans to enroll 34 participants.

Study design
This is an interventional study where participants will use the Medtronic 780G automated insulin delivery system. It plans to enroll 34 participants.
What's involved
Participants in the Medtronic AID treatment group will use the device for three months.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured from baseline to 3 months, suggesting follow-up during this period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07287943

To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

Recruiting
NAAges 18+InterventionalTreatment
Viral N. Shah
~34 participants
Updated 2026-02-18 on ClinicalTrials.gov
What's tested:Medtronic 780G AID

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time in Range (70-180 mg/dL)
Measured over Baseline to 3 months

Conditions

Type 1 Diabetes
Gastroparesis Due to Diabetes Mellitus Type I

Explore related trials

GastroparesisType 1 Diabetes Mellitus

Where it's being run

1 sites across 1 states
Indiana1

Who to contact

Sana Kalaji
[email protected]
317-278-6017
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years
Diagnosis of T1D for at least 12 months with stable insulin regimen for at least 2 months
HbA1c ≥8.0%
Diagnosis of gastroparesis per National Institute of Health (NIH) definition
Willing to use Medtronic 780G system either with Simplera CGM.
Ability to provide informed consent before any trial-related activities
If randomized to usual care group and on an insulin pump already, should be willing to use pump in manual mode only for the duration of the study

Exclusion

Age \<18 years
Current use of inhaled insulin (Afrezza)
Patients with T1D using any glucose lowering medications other than insulin at the time of screening
Pregnancy, breast feeding, or wanting to become pregnant
Current use (≥ 2 weeks of continuous use) of any steroidal medication, or anticipated long-term steroidal treatment (\>4 weeks continuously), during the study period
History of gastric outlet obstruction or other gastrointestinal structural abnormalities
Estimated glomerular filtration rate (eGFR) \<30 or on dialysis
History of SH in the previous 3 months
History of two or more episodes DKA requiring hospitalization in the past 12 months
Any medical (such as severe cardiovascular disease, malignancy, chronic liver disease) or psychosocial conditions that make a person unfit for the study at the discretion of investigators
Use of investigational drugs within 5 half-lives prior to screening
Current use of cannabis or history of cannabinoid hyperemesis syndrome

What this trial measures

  • Time in Range (70-180 mg/dL)Baseline to 3 months

    Percentage of time that sensor glucose values are within the target range of 70-180 mg/dL, as measured by continuous glucose monitoring (CGM).